Within the family of protein kinase C (PKC) molecules, the novel isoform PRKCE (PKCe) acts as a bona fide oncogene in in vitro and in vivo models of tumorigenesis. Previous studies have reported expression of PKCe in breast, prostate and lung tumors above that of normal adjacent tissue. Data from the cancer genome atlas suggest increased copy number of PRKCE in triple negative breast cancer (TNBC). We find that overexpression of PKCe in a non-tumorigenic breast epithelial cell line is sufficient to overcome contact inhibition and results in the formation of cellular foci. Correspondingly, inhibition of PKCe in a TNBC cell model results in growth defects in two-dimensional (2D) and three-dimensional (3D) culture conditions and orthotopic xenografts. Using stable isotope labeling of amino acids in a cell culture phosphoproteomic approach, we find that CTNND1/p120ctn phosphorylation at serine 268 (P-S268) occurs in a strictly PKCe-dependent manner, and that loss of PKCe signaling in TNBC cells leads to reversal of mesenchymal morphology and signaling. In a model of Ras activation, inhibition of PKCe is sufficient to block mesenchymal cell morphology. Finally, treatment with a PKCe ATP mimetic inhibitor, PF-5263555, recapitulates genetic loss of function experiments impairing p120ctn phosphorylation as well as compromising TNBC cell growth in vitro and in vivo. We demonstrate PKCe as a tractable therapeutic target for TNBC, where p120ctn phosphorylation may serve as a readout for monitoring patient response.
INTRODUCTION
Protein kinase C (PKC) molecules belong to the AGC kinase superfamily and are divided into one of three classes (conventional, novel or atypical) determined by dependence on the second messengers Ca 2 þ and diacylgycerol for activation. 1 Although several PKC isoforms have been implicated in cancer, only the novel isoform e is causative for tumor formation in in vitro and in vivo cancer models. 2 Expression of the novel isoform PRKCE (PKCe) is elevated in breast, prostate and lung tumors compared with normal adjacent tissue. 3 Pioneering studies in immortalized murine cells showed that overexpression of PKCe is sufficient to promote growth in soft agar and tumor formation in nude mouse xenografts. 4, 5 Further, transgenic overexpression of PKCe in the mouse prostate leads to invasive prostatic intraepithelial neoplasia, while knockout of even a single prkce allele is sufficient to impair tumorigenesis in a genetically engineered mouse model of prostate cancer. 6, 7 Recent data suggest that PKCe is indispensable for wound closure, cytokinesis and migration; all of which point toward involvement in epithelial to mesenchymal transition (EMT). 8, 9 PKCe has also been implicated in several steps required for the EMT migratory phenotype. 10, 11 EMT of epithelial cancers is linked to a broad transcriptional network induced by a set of embryonic transcription factors. 12 The activity of this transcriptional network is generally scored by loss of epithelial markers, such as E-cadherin, and gain of mesenchymal-specific markers, such as N-cadherin and vimentin. 13 Although the transcriptional network of EMT has been extensively studied, post-translational mechanisms that mediate the effects on cell morphology are not well understood. 14 Here, we report that PKCe expression in normal mammary ducts is confined to myoepithelial cells, and this compartmentalization is lost in breast cancer tissue. Exogenous expression of PKCe is sufficient to overcome contact inhibition in the non-tumorigenic breast epithelial cell line MCF10A. We also show that PKCe activity in triple negative breast cancer (TNBC) cells is tightly correlated with phosphorylation of p120ctn on S268. Furthermore, activation of oncogenic Ras induces a cell morphology and signaling response that is dependent on PKCe activity. We present data validating PKCe as a small molecule inhibitor target for oncology, and propose that high p120ctn P-S268 may reflect PKCe activity in cancer cells. Consequently, analysis of the TNBC subgroup within the invasive breast cancer genome atlas finds PRKCE in the top 2% for all copy number gains (Figure 1b) . In agreement with this data set, we find that immortalized but non-tumorigenic MCF10A breast epithelial cells express low levels of PKCe compared with a panel of cell lines derived from breast malignancies. Moreover, the TNBC cell lines MDA-MB-231 and BT549 express constitutively phosphorylated, or primed, PKCe, indicating hyperactivation of the kinase in this context (Figure 1c) .
RESULTS

PKCe expression drives focal growth in non-
To test the hypothesis that PKCe may drive tumorigenesis in breast epithelial cells, we engineered MCF10A cells to express wild-type PKCe (WTe), the kinase-defective mutant (K437R) or an empty vector control upon exposure to Dox. Dox-mediated induction of WTe and K437R mutant expression in each stable line is shown in Figure 1d . Plated in the absence of Dox, each stable MCF10A variant reached confluency and became contact inhibited (Figure 1d ) as did the empty vector control and K437R in the presence of Dox. Upon induction of WTe, however, cells overcame contact inhibition and cellular foci developed throughout the plating surface, a hallmark of transformation in culture PKCe is required for the growth of triple negative MDA-MB-231 breast cancer cells in vitro and in vivo To further explore the role of PKCe in a disease relevant model, we engineered MDA-MB-231 cells to stably express Dox-inducible shRNAs targeting PKCe. MDA-MB-231 cells are derived from a TNBC with activating mutations in KRAS and BRAF. Induction of PKCe knockdown for an extended period (10 days) resulted in reduced cell density over time, while the uninduced cells and those harboring the non-targeting (NT)-shRNA displayed no obvious growth or survival defect (Supplementary Figure 3) . The PKCe loss of function (LOF) phenotype in two-dimensional (2D) growth conditions prompted us to explore more stringent threedimensional (3D) culture conditions by growing the cells embedded in an extracellular matrix (ECM). In this environment MDA-MB-231 cells form invasive structures, 15 and expression of NT shRNA, the PKCe-targeting hairpin A also resulted in MDA-MB-231 xenograft attrition (23%) even without Dox-administration albeit to a lower extent than with Dox ( Figure 2c ). We hypothesize that this is due to leakiness of inducible shRNA expression resulting in B50% lower PKCe levels in the absence of Dox as reflected by western blot analysis (Figure 2c inset).
p120ctn phosphorylation at S268 in TNBC is tightly linked to PKCe activity Although the genetic gain of function and LOF studies in MCF10A and MDA-MB-231 support an oncogenic role for PKCe, it is difficult to attribute phenotypical alterations to specific pathway modulation without a discrete signaling readout. Therefore, we used MDA-MB-231 cells stably expressing inducible PKCe or NT shRNAs to perform a SILAC (stable isotope labeling by amino acids in cell culture) phosphoproteomic screen and identify possible biomarkers of PKCe activity (Figure 2d ). Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was performed on SILAC-labeled lysates and phospho-enriched peptides with changes greater than two-fold in PKCe knockdown are listed in Supplementary Table 1. Phosphosignal reduction of a-catenin, b-catenin, d-catenin, OB-cadherin and Desmoplakin under PKCe knockdown conditions suggested that PKCe has an especially important role in regulating adherens junction. The phosphorylated d-catenin (herein referred to as p120ctn) peptide identified in the MS analysis corresponds to S268. Knockdown of PKCe by two independent shRNAs (A and B) results in a reduction in the phosphorylation of S268 as compared with the non-silencing control (Figure 2a ).
To further validate the effect of PKCe on p120ctn P-S268, we evaluated the MDA-MB-231 cells stably overexpressing WTe and K437R, and found P-S268 increased in only the WTe-expressing cells (Figure 2e ). Induction of WTe in MCF10A cells, but not the K437R or vector control, also results in elevated P-S268 p120ctn ( Figure 2f ). Likewise, P-S268 p120ctn induction in the MCF10A model could be visualized by immunocytochemistry upon expression of PKCe (Figure 2g ). To explore a possible direct relationship between PKCe and p120ctn, we performed standard in-vitro protein kinase assays using full-length p120ctn immunopurified from mammalian cells as substrate. Indeed, incubation of full-length p120ctn with purified PKCe in vitro resulted in direct phosphorylation of p120ctn at S268 (Figure 2h ). We were unable to detect P-S268 signal by IHC analysis of the tissue microarray, however, IHC of total p120ctn in normal and malignant breast tissues was successful (Figure 1a) . In normal tissue, p120ctn expression is segregated from PKCe and confined to the membrane of epithelial cells of the mammary duct. In the tumor cases, however, we find that p120 staining is reduced at the epithelial membrane with granular intracellular staining accompanying PKCe expression ( Figure 1a) .
As p120ctn phosphorylation state is tightly regulated by PKCe activity, we sought to determine whether p120ctn functions as a crucial mediator of PKCe-driven growth effects. MDA-MB-231 cells were stably engineered to express inducible p120ctn shRNA molecules (Supplementary Figure 2b) . Although no defect in growth was observed in 2D cell culture conditions, induction of p120ctn-specific shRNA molecules A and B showed distinct inhibitory effects on MDA-MB-231 invasive behavior and growth when embedded in ECM (Supplementary Figure 2b) , thereby phenocopying the results obtained with shRNA targeting PKCe.
Oncogenic H-Ras activation results in a PKCe-dependent mesenchymal phenotype Given the modulation of adherens junction protein's phosphorylation state observed in the SILAC experiment and the known role of p120ctn in stabilizing E-cadherin, we hypothesize that PKCe activity could contribute to cadherin remodeling. Indeed, knockdown of PKCe was sufficient to rescue E-cadherin protein levels in MDA-MB-231 and BT549 TNBC cells (Figure 3a and Supplementary  Figure 4a ). Further upon induction of PKCe expression in MCF10A cells, we find that less E-cadherin is associated with p120ctn as assayed by immunoprecipitation (Figure 3b ).
HeLa cells engineered to stably express a 4-hydroxytamoxifen (4-OHT) responsive form of oncogenic H-ras, ER-Ras V12 , undergo a mesenchymal morphology shift when exposed to 4-OHT ( 16 ; Figure 3c ). PKCe knockdown in this context reverted the Ras V12 -induced cell morphology (Figure 3c ). Correspondingly, a change in HeLa cell morphology similar to that induced by Ras V12 was observed by expression of a constitutively active variant of PKCe (Supplementary Figure 5) . Further, induction of Ras V12 signaling in HeLa cells resulted in a significant increase in P-S268 that was sensitive to knockdown of PKCe by antisense oligonucleotides (Figure 3d ). In this model, and to a lesser extent in the MDA-MB-231 model, we observe a reduction in total p120ctn upon PKCe knockdown, perhaps due to impaired stability of p120ctn upon dephosphorylation (Figures 2a and 3d) . Of particular note, we observed an increase in total PKCe levels in the presence of activated Ras, (Figure 3d ) which we quantified in a 4-OHT dose escalation (Figure 3e ). 4-OHT dose-responsive phosphorylation of canonical Ras pathway targets Akt (S473) and MAPK (Y-202/242) were also recorded in this model. In summary, these data suggest that, aside from its inherent oncogenic activity, PKCe is upregulated by oncogenic Ras activation and functions as a mediator of Ras-dependent p120ctn phosphorylation.
PF-5263555, a PKCy-targeted inhibitor, is also potent against PKCe PF-5263555 is an orally available 5-aryl/heteroaryl-3-pyridinecarbonitrile previously developed as an inflammation therapeutic targeting PRKCQ (PKCy) (Figure 4a ; 17 ). We took advantage of the reported cross-selectivity for PKCe in an IMAP biochemical assay and revisited this aspect in the more sensitive UltraLance assay format. 17 The Km for ATP of PKCe by UltraLance was 4.4 mM with PF-5263555 showing classical ATP-competitive kinetics with an IC 50 (50% inhibition of enzyme activity) of 1.2 nM obtained at 5 mM ATP concentration (Figure 4b) .
We established a cell-based assay for testing the effectiveness of PF-5263555 and structurally related derivatives on PKCe based on a methodology described by Cameron et al. 18 and Ohno et al.
19
Here, binding of ATP-competitive inhibitors by the kinase dead version of the enzyme primes the hydrophobic motif in the catalytic domain for phosphorylation by its upstream-activating kinase. Applying this approach, PF-5263555 exhibited an IC 50 of B250 nM in cells as reflected by its ability to induce the phosphorylation of S729 in the K437R PKCe ( Figure 4c ). As predicted by Cameron et al. 18 overexpressed WT PKCe is constitutively phosphorylated at this site and no further phosphosignal is observed upon addition of PF-5263555 (Figure 4c) .
The in vitro IC 50 results for a spectrum of PKC enzymes have been published previously, highlighting the selectivity of PF-5263555 for PKCe and PKCy. 17 As PKCy cannot be detected by western blotting in HeLa ER-Ras V12 or MDA-MB-231 cells, the selectivity for PKCy and e over PKCd and Z indicates that PKCe is the major, if not sole, target for PF-5263555 in these cellular models.
PF-5263555 normalizes Ras-driven morphology, PKCe-driven focal growth and PKCe-p120ctn signaling Given the activity of PF-5263555 against PKCe, we attempted pharmacological recapitulation of PKCe knockdown in in-vitro and in-vivo models of Ras V12 -mediated EMT and breast cancer growth. Similar to the results attained using antisense knockdown of PKCe, treatment of Ras V12 HeLa cells with PF-5263555 resulted in a reversion of the cellular morphology promoted by Ras V12 activation (Figure 4d) . Treatment of the Hela ER-Ras V12 cells with PF-5263555 also resulted in loss of P-S268 signal (Figure 4e ).
To interrogate possible downstream effects of p120ctn P-S268, we generated S268A and S268E mutants mimicking the dephosophorylated and phosphorylated sites, respectively. As expected, inhibition by PF-5263555 reduced P-S268 in both the overexpressed and endogenous p120ctn; however, the phosphospecific antibody failed to recognize both the S268A (nonphoshpo) and the S268E (phospho-mimetic) mutants (Figure 4f and Supplementary Figure 4b) . We found that PF-5263555 reduced b-catenin levels, whereas overexpression of the S268E mutant protein resulted in higher basal b-catenin levels, largely refractory to PKCe inhibition (Figure 4f) . Correspondingly, in ERRas V12 HeLa cells, b-catenin levels were reduced upon antisense knockdown of PKCe in the absence and presence of Ras activation (Figure 3d) . Finally, by blocking global translation with cyclohexamide and assaying b-catenin decay over time, we find that overexpression of p120ctn in HeLa cells elevates b-catenin expression and reduces decay compared with vector control (Supplementary Figure 4c) . Both S268A and S268E p120ctn mutants also stabilized total b-catenin with the S268E mutant having a more pronounced effect at time 0 (Supplementary Figure 4c) . Thus, it is likely that elevated p120ctn expression contributes to overall stability of b-catenin, and in this context phosphorylation at S268 is a positive effector.
Given that focal growth observed in MCF10A cells can be driven by PKCe expression, treatment with PF-5263555 should be sufficient to revert cells to contact inhibition. Indeed, PF-5263555 treatment of MCF10A cells expressing PKCe results in loss of foci formation (Figure 4g ). When the downstream signaling was interrogated in these cells, we also observed reduced p120ctn P-S268 with addition of PF-5263555 (Figure 4h ).
PF-5263555 inhibition of PKCe recapitulates the genetic LOF phenotype in cells and inhibits tumor growth in vivo
In agreement with previous experiments, PF-5263555 treatment of MDA-MB-231 cells stably expressing WTe significantly attenuated p120ctn P-S268 signal (Figure 5a ). Treatment of both, BT549 and MDA-MB-231 cells with PF-5263555 resulted in a rescue of E-cadherin levels, substantiating the role for PKCe in maintaining an EMT-dependent phenotype in TNBC cells (Figure 5b and Supplementary Figure 4d) . PF-5263555 also produced a dosedependent change in MDA-MB-231 morphology characterized by a flattened epithelial-like morphology (Figure 5c ). Likewise, 
DISCUSSION
Various PKC family members have been previously implicated in driving the malignant state of cancer cells. 20 Early efforts in oncology drug discovery to target PKC have largely focused on the cancer cell autonomous effects of PKCa (ISIS 3125, PKC412, UNC101) or the pro-angiogenic effects of PKCbII (Enzastaurin). 1 To date, targeting PKCs has been met with limited clinical success due to poor compound properties or pleiotropic pharmacological effects, leading to dose-limiting toxicity before reaching efficacy. Based on our results, we propose the specific targeting of the novel isoform PKCe, as this kinase has oncogenic properties when expressed at elevated levels in cell culture and in transgenic mouse models. Recently, mesenchymal stem cell sub-populations isolated from an immortalized mammary epithelial cell line were described as enriched for PKC pathway activation. 21 Further, by forcing the bulk population of mammary epithelial cells to undergo EMT, strong activation of PKC pathways was observed. 21 Other groups have related EMT specifically to PKCe in human cancer through mir205 activity and more recently through a c-MET/mir103-signaling axis in lung cancer. 22, 23 Previous studies by the Ivaska and Parker labs have described PKCe involvement in integrin recycling and zonula occludens stability, providing a mechanistic explanation for the observed effects of PKCe on cell invasion. 10, 11 Profiling studies of tumor samples from breast cancer patients and cell lines have revealed a stem cell-like gene signature associated with EMT. 24 Of particular relevance is the finding that breast cancer samples with stem celllike characteristics show upregulated b-catenin and OB-cadherin mRNA, both of which were also identified as being modified in our SILAC analysis in a PKCe-dependent manner.
To the best of our knowledge, no previous reports have linked deregulation of the armadillo catenin members in response to loss and/or inhibition of PKCe. In the phosphoproteomic screen presented here we see a reduction in phosphorylated peptides of a-catenin, b-catenin, Desmoplakin, and p120ctn. Although p120ctn S879 was reported to become phosphorylated upon treatment with PDGF in a PKCa-dependent manner, the PKC isoforms responsible for other p120ctn-specific phosphorylation events have remained largely unknown. 25, 26 This may explain the conflicting results from Xia et al., 27 where P-S268 is downregulated upon high PKC activity. Previous studies have reported opposing effects on growth and proliferation mediated by PKCd and PKCe. 4 Thus, it is possible that activation of the tumor-suppressive PKCd in the context outlined by Xia et al. 27 has a dominant effect over PKCe activity, resulting in a net dephosphorylation of S268.
Tyrosine phosphorylation of p120ctn has previously been reported in response to activation of oncogenic Src. 28 Although this phosphorylation does not alter its binding to E-cadherin, it does result in a reduction in cell adhesion. Further, constitutive Src-and Rac-mediated anchorage-independent growth was found to be p120ctn dependent. 29 Suprisingly, however, oncogenic H-Ras-mediated anchorage-independent growth was refractory to p120ctn knockdown in MDCK cells. 29 This may be partly explained by the work of Soto et al. 30 who describe a tumor-suppressive function for p120ctn when E-cadherin is high (as in the case of MDCK cells), but oncogenic when E-cadherin is low as in the case of MDA-MB-231 breast cancer cells. Similarly, Shibata et al. 31 describe an oncogenic role for p120ctn in E-cadherin low breast cancer cell lines and cytoplasmic localization of p120ctn when E-cadherin is absent. Mislocalization of p120ctn from cell junctions to cytoplasm has been reported in colon cancer cells undergoing EMT. 32 Not surprisingly, then loss of E-cadherin in breast cancer patients correlates well with cytoplasmic localization of p120ctn, and both of these factors independently predict poor outcome with respect to patient survival and disease progression. 33 Although different Ras isoforms (that is, H-, K-and N-) are not interchangeable in regards to cellular phenotype, our results suggest that activated Ras can mediate changes in cell morphology that are dependent on PKCe signaling. Integrin signaling through focal adhesion kinase has been reported to be essential to Ras-driven transformation, and Ras signaling is frequently associated with cadherin switching in EMT progression. 34, 35 Although Ras mutations are not common in breast cancers, there are multiple paths to activated Ras where PKCe may be a downstream effector, such as loss of the Ras-GAP NF1 or the miRNA let-7. 36, 37 In light of the data presented here, correlation of PKCe expression in breast cancer patients with expression and localization of adherens junction proteins, including p120ctn, may be useful in generating patient stratification hypotheses. Our data further indicate that PKCe is an important mediator of Ras signal transduction and malignant growth in TNBC cells, and represents a unique opportunity for the development of targeted cancer therapies.
MATERIALS AND METHODS
Antisense-mediated knockdown
Third-generation genebloc antisense molecule gapmers 38 were synthesized by Biospring (Frankfurt, Germany). Each antisense molecule used was controlled by a corresponding 4 nucleotide control oligonucleotide. Transient knockdown experiments, and subsequent signaling or phenotypic analysis were carried out as described previously. 38 Briefly, GAPmer oligonucleotides targeting PRKCE were transfected with Atufect transfection reagent (Silence Therapeutics, Berlin, Germany). HeLa ER-Ras V12 cells were seeded 300 000 cells/10-cm plate, 24 h before transfection. Oligonucleotide and transfection reagent were complexed according to the manufacturer's instructions and delivered to cells at a final concentration of 30 nM and 1.2 mg/ml, respectively. Antisense oligonucleotide sequences used in this study are found in Supplementary Table 2. 3D cell culture assays Experiments involving MDA-MB-231 cells used an ECM-embedded protocol as follows. MDA-MB-231 cells engineered with inducible shRNA constructs were induced with 250 ng/ml Dox for 48 h before embedding in 300 ml of ice-cold 80% liquid ECM (BD Biosciences) 20% full media. A total of 100 000 cells were resuspended in ECM. This ECM cell suspension was allowed to harden for 2 h, and 1 ml of media supplemented with vehicle, Dox or PF-5263555 was added.
MDA-MB-231 orthotopic xenografts and PF-5263555 dosing MDA-MB-231 stable cells (1 Â 10 6 ) expressing Dox-inducible PKCe or NT shRNAs cultured in the absence of Dox were injected orthotopically into the right abdominal mammary fat pad of female nude mice. Groups of 15 mice received mammary fat pad inoculation of pooled PKCe or NT shRNAs, expressing MDA-MB-231 cells. Dox was administered through food at 625 mg/kg. All animals were completely dissected and photographically documented.
For compound efficacy experiments, 1 Â 10 6 MDA-MB-231 cells were injected orthotopically into the right abdominal mammary fat pad of female nude mice. When tumors reached an average tumor volume of
SILAC phosphoproteomic LC-MS/MS
Equal amounts of light and heavy arginine/lysine isotope samples were combined and subjected to proteolytic digestion with Lys-C, trypsin and Glu-C. Phosphopeptides were enriched by strong-cation exchange fractionation followed by the titanium dioxide chromatography, as described previously. 39 Peptide identification and relative quantification were performed on a reversed-phase Magic C18 nanocolumn coupled with an LTQ-Orbitrap XL mass spectrometer (Thermo Fisher, Waltham, MA, USA). MS/MS raw spectra were searched against the human IPI database using Biowork 3.3.1 (Thermo Fisher). The relative ratio of the intensity of the heavy versus the light peptides was used to express the degree of phosphorylation change of a given protein.
In vitro and cell-based PKC assays
The inhibitory potency of compounds against PKCe was determined in the LANCE Ultra kinase assay format. The assay was carried out in a white 384-well plate (Matrix Technologies, Hudson, NH, USA) by incubation of PKCe (5 pM, Invitrogen, Grand Island, NY, USA) with inhibitor, Ulight-labeled peptide substrate (50 nM CRFARKGSLRQKNV, Perkin Elmer) and ATP (5 mM) in assay buffer (20 mM HEPES, pH 7.2, 2.5 mM MgCl 2 , 2 mM Cys, 0.005% Brij35). The reaction was stopped with EDTA (20 mM) after 60 min incubation at room temperature. The formation of phosphopeptide product was determined by Europium-labeled anti-phospho PKC (A25S) antibody (1 nM, Perkin Elmer, Waltham, MA, USA). The TR-FRET signals at 615 and 665 nm wavelengths upon excitation at 340 nm were measured using the Envision fluorescence plate reader from Perkin Elmer. The signal ratio of 665/615 (Ulight/Europium) was used in all data analyses. The IC 50 value was obtained by fitting the data to a dose-response inhibition equation using GraphPad Prism (GraphPad Software, Inc., La Jolla, CA, USA).
The cell-based assay of KD PKCe P-S729 was performed in engineered MDA-MB-231 cells described above. Cells were treated with PF-5263555 in a dose response for 24 h, lysed and analyzed by western blot as described below. Rationale and full description of this approach can be found in Cameron et al.
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Molecular cloning, viral preparations and stable cell-line engineering The 4-OHT-inducible oncogenic form of H-Ras, ER-Ras V12 , has been previously described. 16 PKCe and p120ctn expression plasmids suitable for lentiviral recombination were created using Invitrogen's ViraPower Lentiviral Expression Systems (b-galactosidase, b-Gal, control supplied by Invitrogen). Briefly, PRKCE and CTNND1 open-reading frames were cloned into pENTR-D followed by transformation into TOP10 competent Escherichia coli (Invitrogen). Positive clones were sequenced and recombined into pLenti4-TO/V5 or pLenti6.3-TO/V5 through homologous recombination followed by transformation of competent STBL3 E. coli (Invitrogen). Ampicillin/Zeocin-or Ampicillin/Blasticidin-resistant colonies were screened by PCR and prepared as endofree plasmid (Qiagen, Germantown, MD, USA). Site-directed mutagenesis was performed on pENTR-D-PKCe to create kinase-inactive (K437R) and constitutively active (A159E) forms as well as pENTR-D-p120ctn to create S268A and S268E mutants. All shRNA lentiviral plasmids were constructed using annealed oligonucleotides using standard cloning methods into the pLentiCiti 7SK vector. 40 Primer sequences used for cloning steps including shRNA sequences are found in Supplementary Table 2 .
Pseudotyped retroviral particles were created by transfecting the packaging cell line GP2-293 with pLIXN-ER-Ras V12 (5 mg) and pVSVG (7 mg) using Effectene transfection reagent (Qiagen) in the presence of 2.5 mM chloroquine. The next day media was aspirated and replaced with full media without chloroquine, and retroviral particles were harvested after 3 days. Pseudotyped lentiviral particles (harboring shRNA or PKCe, b-Gal and p120ctn expression cassettes) were obtained through similar methodology except that the packaging cell line used is 293-FT, and 7 mg of the virapower packaging mix (Invitrogen) was co-transfected with 5 mg of lentiviral plasmid DNA. 40 Stable HeLa and MDA-MB-231 cell lines were created by exposing cells at 50% confluency in a six-well plate to pseudotyped retroviral or lentiviral particles at a multiplicity of infection of one or less for a 24-h period in the presence of 8 mg/ml polybrene. After 24 h media was replaced with full media, cells were grown to confluence and then passaged into T-175 culture flasks with the appropriate selection (G418 at 500 mg/ml, Blasticidin at 10 mg/ml or Zeocin at 100 mg/ml) until resistant cell colonies formed, and antibiotic induced cell death ceased. Several hundred resistant colonies were pooled and expanded to form the stable cell lines employed herein.
Immunoblotting and immunoprecipitations
Standard western blotting techniques were used for all immunblotting experiments described. Cell lysates were generated from 2D and 3D growth conditions using RIPA buffer containing 40 mM HEPES, pH 7.5, 120 mM NaCl, 1 mM EDTA, 5% glycerol, 1% NP40, 1% Na deoxycholate, 0.1% SDS, protease inhibitor cocktail (Sigma-Aldrich, St Louis, MO, USA) and phosphatase inhibitor cocktails I and II (Sigma-Aldrich). Antibodies used in this study are found in Supplementary Table 3 .
Immunoprecipitations were performed using antibodies indicated in Supplementary Table 3 . In brief, cells were lysed in CHAPS-based lysis buffer containing 40 mM HEPES pH 7.5, 120 mM NaCl, 1 mM EDTA, 5% glycerol, 1% CHAPS, protease inhibitor cocktail (Sigma-Aldrich), and phosphatase inhibitor cocktails I and II (Sigma-Aldrich). Upon removal of cell debris by centrifugation, lysates were precleared with protein G GammaBind beads (GE Healthcare, Buckinghamshire, UK) with rotation for 1 h at 4 1C. Protein A beads were removed and mouse monoclonal antip120ctn antibody was added to a final concentration of 1/250 mg protein with rotating incubation overnight at 4 1C. p120ctn immunocomplexes were captured with protein G GammaBind beads by constant rotation for 4 h at 4 1C, recovered by centrifugation and then washed six times with ice-cold CHAPS lysis buffer. p120ctn immunocomplexes were eluted with standard SDS gel-loading buffer by boiling for 5 min and analyzed by standard western blotting techniques.
Microscopy, immunocytochemistry and IHC
Micrographs of live cells grown in 2D and 3D cell culture were taken using phase contrast settings on a Zeiss Axioscope (Carl Zeiss AG, Oberkochen, Germany) at the indicated magnifications. Focal growth was quantified from images recorded at identical focal plane, brightness and exposure in phase contrast conditions at Â 2.5 magnification. Microscopy images were analyzed using the Adobe Photoshop CS5 (Adobe Systems Inc., San Jose, CA, USA) extended version measurements tool, where integrated density of the micrograph is calculated from the product of the image area (in pixels) and the mean gray value (measurement of image brightness). Immunoflourescence was carried out on cells grown on collagen-coated coverslips. Briefly, cells were fixed with 4% paraformaldehyde in Phosphate-buffered saline (PBS) and permeabilized with 0.5% Triton X-100 PBS. Samples were washed and blocked with 3% BSA in PBS, and then incubated for 1 h with primary antibody. Cells were washed (PBS) before a 30 min incubation with Alexaflour488 (Invitrogen)-conjugated secondary antibody (Invitrogen) and then washed again. Cells were mounted on slides with Gold antifade mounting media with 4',6-diamidino -2-phenylindole and phalloidin stains. Micrographs of immunofluorescent labels were taken on a Zeiss confocal microscope (Carl Zeiss AG, Oberkochen, Germany) at the indicated magnification.
IHC was performed on formalin-fixed paraffin-embedded tissue sections using standard protocols and developed through 3,3-Diaminobenzidine detection and horseradish peroxidase conjugated secondary antibody. Tissue microarrays with both normal and tumor tissue were procured from US Biomax (BR1921). Slides were conterstained using standard hematoxylin staining protocol.
Statistical methods
Western blots and phase contrast microscopy were quantified by using the Adobe Photoshop CS5 extended version measurements tool based on overall brightness. For western blots, arbitrary units of brightness normalized to a loading control were compared between experimental conditions by two-tailed Student's t-test assuming unequal variance. For phase contrast images arbitrary units of the reciprocal function from integrated density values were compared between experimental conditions by two-tailed Student's t-test assuming unequal variance. In-vivo tumor growth was measured weekly using standard caliper measurements and statistically analyzed using repeated measures analysis of variance.
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